RaySearch Laboratories AB (publ) Interim Report January 1- March 31, 2009 JANUARY 1 - MARCH 31, 2009 • Net sales for the period totaled SEK 16.9 M (15.6) • Profit after tax was SEK 7.3 M (3.1) and earnings per share amounted to SEK 0.21 (0.09) • Operating profit was SEK 9.9 M (3.6) • Cash flow totaled SEK 8.7 M (neg: 5.5) • The collaboration with Nucletron was extended in January with two new products for treatment planning • The first product from the collaboration with TomoTherapy received FDA clearance in January and has been launched AFTER THE CLOSE OF THE PERIOD • The new VMAT product from the collaboration with Philips received FDA clearance and was launched in April • A collaboration agreement with Siemens was signed in May ”We are very pleased to announce today a new partnership with Siemens. The agreement is of strategic importance for RaySearch as Siemens is one of the leading global suppliers of equipment for radiation therapy,” says Johan Löf, CEO of RaySearch ”Both revenues and profit increased during the first quarter. In addition, two new products have been launched on the market and several more are on the way, so I am very pleased with RaySearch's current development”, concludes Johan Löf. FOR FURTHER INFORMATION, PLEASE CONTACT: Johan Löf, President and CEO Telephone: +46 (0)8-545 061 30 johan.lof@raysearchlabs.com ABOUT RAYSEARCH RaySearch Laboratories is a medical-technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch's products are sold through license agreements with leading partners such as Philips, Varian, Siemens, Nucletron, IBA Dosimetry and TomoTherapy. Ten products have been launched to date and RaySearch's software is used at over 1,300 clinics in more than 30 countries. In addition, existing license agreements cover more than 15 other products that are scheduled to be launched in the coming years. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on the OMX Nordic Exchange Stockholm. For more information about RaySearch, visit www.raysearchlabs.com.
RaySearch Laboratories AB (publ) Interim Report January 1- March 31, 2009
| Source: RaySearch Laboratories AB